Recent Updates
Recently added Catalysts

TD-5108

Phase 2

Chronic Constipation | Small molecule | Gastrointestinal |Theravance Biopharma, Inc.|Last Updated: Jul 8, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment360
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00391820Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)PHASE2 COMPLETED 360Oct 1, 2006May 1, 2007Jul 8, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
- Clinical response
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
TD-5108DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Meet ROME III Criteria Exclusion Criteria: * Constipation caused by:colonic etiology, pelvic floor dysfunction, metabolic disturbances, neurologic disturbances,concomitant medications affecting bowel function * Chronic treatment with anticholinergics, narcotic analgesics * I...

Countries:United States
Unlock Eligibility Criteria